Tag Archives: finance

Hot Investor Mandate: Canada-Based VC Invests in AI-Driven Technologies Including Medical Devices, Diagnostics, and Digital Health Across the Globe

5 Aug

A venture capital corporation is based in Canada with the government serving as a limited partner participates in Angel through Series A rounds, typically allocating CAD $100K to $200K for Angel rounds and CAD $500K to $1M for Pre-A and Series A rounds. It is open to co-investments and occasionally acts as a limited partner in other investment funds. The firm seeks innovative projects that align with the interests of its affiliated operating company, which specializes in immunology-based diagnostics. 

In addition to direct investments, the firm in-licenses intellectual property from universities and engages in joint ventures with other partners. With its own internal management and engineering team, the firm plays an active role in helping startups enter the market and commercialize their products. The firm is open to working with companies globally. 

Its core areas of interest include AI-driven digital health, medical devices, and diagnostics – particularly those involving antigen and antibody pairs. The firm favors companies that are nearing commercialization and can be integrated into its existing AI platform. A board seat is typically preferred in investments. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Get on Pharma’s Radar: What Big Companies Look for in Early-Stage Innovation

5 Aug

Live at RESI Boston – September 17 | Westin Copley Place 

By Momo Yamamoto, Senior Investor Research Analyst, LSN

For many early-stage life science companies, partnering with a major pharmaceutical firm can be a transformative milestone. Beyond capital, Big Pharma brings global reach, regulatory know-how, and commercialization muscle, opening doors that would otherwise be out of reach. But breaking through the noise and earning that opportunity requires more than a strong pitch deck.

The “Partnering with Big Pharma” panel at RESI Boston will offer a rare, inside look at how business development and licensing leaders identify and evaluate emerging innovation, including therapeutics and enabling technologies.

What Does Big Pharma Look For?

This 50-minute session will dive into the key criteria pharma decision-makers use to vet early-stage companies. From the strength of the data package and differentiation in a crowded landscape to alignment with therapeutic priorities and unmet need, the panel will shed light on how early is too early and when is just right to engage.

Attendees will also gain insight into how large pharma teams structure search & evaluation processes, how red flags are interpreted, and what signals strong partnership potential.

 Moderated by Jeremy Sohn, Managing Partner at P74 Ventures, this conversation brings together key voices shaping pharma’s external innovation strategy:

Jeremy-Sohn Hyelim-Cho Nikhil-Mutyal
Jeremy SohnManaging Partner
P74 Ventures
(Moderator)		 Hyelim ChoSenior Director, BD and Alliance Management
RayzeBio
(a Bristol Myers Squibb company)		 Nikhil MutyalHead of Search and Evaluation, Respiratory and Immunology
AstraZeneca
Armin-Rump Jenny-Wang
Armin RumpDirector of Global Business Development
Otsuka Pharmaceutical Co., Ltd.		 Jenny WangDirector, Search & Evaluation, Oncology
AbbVie

These leaders are actively scouting for high-impact innovations and will share how their organizations assess risk, potential, and fit in a rapidly evolving landscape. You will hear how shifting trends are reshaping pharma’s partnering approach, and what startups can do to stand out in a competitive environment.

Whether you are aiming for a strategic investment, licensing deal, or co-development partnership, this panel offers direct access to the minds shaping pharma’s innovation agenda. Founders, BD professionals, and investors alike will walk away with actionable insights into what it takes to get – and stay on – Big Pharma’s radar.

Register today and save with early bird rates.

Tags: , , , ,

China’s Biotech Boom: Innovation, Influence, and Rising Tensions 

5 Aug

By Sougato Das, President and COO, LSN

Sougato-Das

As 2025 progresses, China’s biotech and pharmaceutical sectors are not just growing—they’re reshaping the global industry landscape. With skyrocketing innovation, bold regulatory reform, and a deepening rivalry with the U.S., Chinese biotech firms are asserting their global presence at unprecedented speed. The GSK / Hengrui Pharma deal, involving a major collaboration potentially worth up to $12.5 billion, is the latest example. The deal focuses on developing up to a dozen drug candidates, primarily in respiratory diseases, immunology, infection, and oncology. GSK will pay Hengrui an upfront fee of $500 million, with the potential for significant milestone payments and royalties if the collaboration is successful. China will continue to play a major role in the worldwide biopharma ecosystem as…

China Emerges as a Global Drug Development Powerhouse

  • Record Licensing Activity: China-to-West drug licensing hit a record $41.5 billion in 2024, a staggering 66% jump from the previous year. Nearly 30% of global innovative drug assets now trace their origin to China.
  • Biotech Licensing Leadership: In 2024, 42% of all global biotech licensing deals over $50 million involved Chinese firms—up from 22% in 2023.

Drug Discovery Is Going East

  • Rapid Shift in Molecule Sourcing: One in three externally sourced molecules by global biopharma firms now comes from China—a dramatic rise from virtually none in 2019. Chinese biotech firms are lauded for their speed, efficiency, and low-cost synthesis of new compounds, positioning them as preferred partners for drug discovery.

Clinical Trials and Regulatory Momentum increases in China

  • China’s Clinical Surge: In 2023, nearly 28% of global clinical trial sponsorships originated from China—up from just 4% a decade ago. Registrations alone rose by 26% last year.
  • Faster to Market: Thanks to reforms by China’s National Medical Products Administration (NMPA), investigational new drugs can now be approved for human testing in just 60 working days.
  • FDA Recognition: Chinese trials are increasingly qualifying for FDA priority pathways, challenging the traditional dominance of U.S.-based clinical development.

China is at the Cutting Edge of Gene Editing

  • CRISPR Leadership: Chinese startups like YolTech (in vivo CRISPR therapy) and Huidagene (brain-targeted CRISPR trials) are leading in next-gen gene editing.
  • Global Recognition: According to Goldman Sachs, China is at the forefront of CRISPR and CAR-T research.

Tensions and Regulatory Hurdles deepen with the US

  • Geopolitical Pressure: Proposed U.S. legislation—the BIOSECURE Act—would prohibit drugmakers with federal contracts from using Chinese firms like WuXi AppTec and WuXi Biologics after 2032. This could disrupt global supply chains and complicate R&D strategies for U.S. companies.
  • Scientific Chilling Effect: Fears of increased scrutiny are causing some Chinese and Chinese-American researchers to avoid applying for NIH grants, impacting U.S.-China scientific collaboration.
  • Investment Headwinds: Despite innovation, venture capital investment in Chinese biotech has declined due to geopolitical uncertainty.

Cross-Border Deals Multiply

  • Western Biopharma Engagement: U.S. and European firms are actively pursuing licensing and partnership deals with Chinese biotechs—particularly in ADC and bispecific antibody platforms, expanding beyond oncology.
  • Investor Sentiment Splits: Some U.S. investors advocate for protectionist strategies, while others see China’s rise as an opportunity for strategic alignment and access to novel therapies.

What Does All This Means for the Industry>

China is no longer simply a “fast follower” in biotech. It’s now an originator of breakthrough science, shaping the future of global drug development, even as geopolitical tensions threaten to redraw the map of international collaboration.

As global biopharma leaders and investors reassess their strategies, one thing is clear: ignoring China’s biotech ascent is no longer an option.

Tags: , , , , , , , , , , ,

JPM 2026: Partnering, Event/Reception Space Available at RESI JPM

29 Jul

Host your event. Launch your brand. Meet your partners.

By Sougato Das, President and COO, LSN

Sougato-Das

Life Science Nation (LSN) has secured a 20,000 square foot (1900 square meters) space at the Marriott Marquis in Union Square in the heart of JPM Week 2026. This premium venue will serve as the headquarters for the Redefining Every Stage of Investment (RESI) conference on Monday and Tuesday, January 12 and 13—but we’re opening the doors Sunday, January 11 for groups looking to host their own event in the center of the action.

We’re inviting economic development agencies, global trade organizations, venture groups, and industry associations to partner with LSN or book standalone time in this flagship location.

The Space

  • 20,000 square feet of meeting and activation space
  • 4 fully equipped conference rooms (2400 square feet/220 square meters), good for theater-style seating for presentations or a small networking event
  • 90+ RESI-style partnering tables
  • Full-service meeting logistics support available

This space is ideal for:

  • Networking receptions, investor briefings, and pitch showcases
  • Country or region-specific innovation days
  • Workshops, roundtables, or startup presentations
  • Private investor or industry partner meetings

Flexible Integration Options

  • January 11 (Sunday): Available for standalone programs, private events, or pre-RESI activities
  • January 12 and 13 (Monday and Tuesday): Integrate into the RESI JPM program, gain access to hundreds of global investors, and use the space to host partner meetings or specialized tracks within the RESI ecosystem

LSN is already in discussion with a range of organizations, including tech hubs, economic development agencies, service providers, and nonprofit patient groups who are seeking affordable options for hosting events and partnering at JPM.

Why Co-Locate with LSN During JPM?

  • Prime Union Square location just steps from the major hotel hubs and investor meetings
  • Built-in foot traffic and visibility from RESI attendees, investors, and partners
  • Flexible use of infrastructure and logistics support from the LSN team
  • Branding and signage opportunities throughout the venue
  • Streamlined meeting scheduling and visibility if integrated into the RESI partnering platform

Make It Yours

Whether you’re looking to host a private country reception, a thematic track inside RESI, or a custom event that aligns with your mission, the space is move-in ready and centrally located. We can help with meeting set-up, agenda development, signage, staffing, registration flow, and more.

Interested in booking or learning more?
Contact salescore@lifesciencenation.com to discuss options, availability, and pricing.

Let’s create a high-impact presence for your organization at the most important week in global life sciences.

Tags: , , , , , , , , , ,

Hot Investor Mandate: VC Firm Headquartered in Asia Makes Early- to Expansion-Stage Investments Into Digital Healthcare Companies With Asia Market Potential 

29 Jul

A venture capital investor based in Asia with a presence in the US makes early- to expansion-stage investments across multiple sectors, ranging from smart cities and fintech to healthcare. Investment size is highly variable depending on the company’s stage. The firm invests alongside other venture capital firms in companies located in North America and Europe that have a market expansion strategy into Asia. 

The firm takes an opportunistic approach to digital healthcare companies, particularly those leveraging AI and bioinformatics to accelerate the drug discovery process. 

The firm seeks entrepreneurs who are passionate, driven, and enthusiastic, with sustainable business models and globally scalable ideas. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: Venture Arm of Investment Bank Seek Therapeutics and Medtech Companies in CNS, Oncology, and More, Focusing on US Based Opportunities

29 Jul

An investment bank headquartered in the US  does not act as a traditional investment bank, as the firm participates in venture capital, investing in and working with early-stage technology and life science companies with the main goal of taking the companies to public markets. The firm has also spun out and out-licensed technologies from universities and has capabilities to help with company formation, business strategy, IP, and early IPOs. The firm utilizes a sister company to further analyze company technologies and IPs. The firm can fund from $5-12M USD from Seed to Series A rounds with preference in US-based companies, though the firm is open to global companies. 
 
The firm is looking at biotech, medical devices, and diagnostics companies and is technology-agnostic. The firm generally does not look at digital health. There has been strong interest in immuno-oncology, neurology, and CNS. 
 

The firm works closely with companies and founders and will lead investment rounds. The firm typically requires taking a board or observer seat while deciding strategy, and once the company goes public, the firm will bring in a board member with expertise in the field. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

Hot Investor Mandate: VC Firm Focuses on Global Early-Stage Medical Device Investments, With Strong Interest in Companies Developing Class III Devices

29 Jul

A venture capital firm, founded in 2019, is a global venture capital investor. The firm specializes in early-stage medical device companies and actively leverages expertise and industry resources to support portfolio companies. The firm prefers taking a leading role in investment rounds and may seek board seats in such cases. 

The firm focuses on medical devices and is open to all subsectors and indications. The firm seeks innovative technologies, primarily investing in Class III devices, and occasionally considers Class II devices if they demonstrate significant innovation. The firm is open to working with companies at all stages, including those in the early idea phase. 

The firm prefers founding teams with strong scientific expertise and comprehensive knowledge of their respective fields. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: , , , ,

← Older Entries
Newer Entries →